Illumina, Inc. announced today that Caroline Dorsa has joined the company’s Board of Directors. Given her financial expertise, Ms. Dorsa will also participate on the Audit Committee of the Board.
Ms. Dorsa has held a number of senior management positions at Merck & Co., Inc., including Senior Vice President of Marketing Strategy and Integration, and Vice President and Treasurer, where she also oversaw investor relations, financial planning for manufacturing and tax. Most recently, as Executive Vice President and CFO at Public Service Enterprise Group, Ms. Dorsa led the finance, business development, and investor relations teams. She is a Director of Biogen Inc. and Intellia Therapeutics, Inc., and a trustee of the Goldman Sachs MLP Income Opportunities Fund and the Goldman Sachs MLP and Energy Renaissance Fund.
“Caroline brings a great breadth of knowledge and experience as a director on major boards and a senior executive at large companies,” said Francis deSouza, Illumina President and Chief Executive Officer. “Her deep understanding of the clinical space will enable Caroline to make a significant contribution to Illumina as we continue to pursue growth in our clinical markets.”
In addition to her service at Merck & Co., Inc. and at Public Service Enterprise Group, Ms. Dorsa served as Senior Vice President and CFO of Avaya, Inc. She received her B.A. from Colgate University and her M.B.A. from Columbia University.
Source: Illumina
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.
